Amicus Therapeutics (FOLD)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Amicus Therapeutics (FOLD)
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Key Insights
Critical company metrics and information
Share Price
$9.86Market Cap
$2.95 BillionTotal Outstanding Shares
298.81 Million SharesTotal Employees
517Dividend
No dividendIPO Date
May 31, 2007SIC Description
Pharmaceutical PreparationsHomepage
https://www.amicusrx.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Exchange Gains/Losses | $-11.04 Million |
| Net Cash Flow From Investing Activities, Continuing | $-4.13 Million |
| Net Cash Flow | $-29.45 Million |
| Net Cash Flow From Investing Activities | $-4.13 Million |
| Net Cash Flow From Financing Activities | $12.23 Million |
| Net Cash Flow From Operating Activities, Continuing | $-26.52 Million |
| Net Cash Flow, Continuing | $-18.41 Million |
| Net Cash Flow From Financing Activities, Continuing | $12.23 Million |
| Net Cash Flow From Operating Activities | $-26.52 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Basic Average Shares | $305.64 Million |
| Costs And Expenses | $562.02 Million |
| Gross Profit | $444.24 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Operating Expenses | $439.03 Million |
| Income Tax Expense/Benefit | $36.34 Million |
| Benefits Costs and Expenses | $562.02 Million |
| Income/Loss From Continuing Operations Before Tax | $-68.35 Million |
| Operating Income/Loss | $5.21 Million |
| Diluted Average Shares | $305.64 Million |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Net Income/Loss | $-104.69 Million |
| Net Income/Loss Attributable To Parent | $-104.69 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Cost Of Revenue | $49.43 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-104.69 Million |
| Revenues | $493.67 Million |
| Selling, General, and Administrative Expenses | $306.95 Million |
| Income/Loss From Continuing Operations After Tax | $-104.69 Million |
| Diluted Earnings Per Share | $0.34 |
| Other Operating Expenses | $132.08 Million |
| Basic Earnings Per Share | $0.34 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Non-current Liabilities | $60.10 Million |
| Accounts Payable | $13.48 Million |
| Other Non-current Assets | $239.62 Million |
| Equity | $178.82 Million |
| Intangible Assets | $18.03 Million |
| Liabilities | $607.73 Million |
| Current Assets | $498.47 Million |
| Current Liabilities | $158.14 Million |
| Other Current Assets | $383.14 Million |
| Equity Attributable To Parent | $178.82 Million |
| Long-term Debt | $389.49 Million |
| Liabilities And Equity | $786.56 Million |
| Assets | $786.56 Million |
| Inventory | $115.34 Million |
| Noncurrent Assets | $288.08 Million |
| Other Current Liabilities | $144.66 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Noncurrent Liabilities | $449.59 Million |
| Fixed Assets | $30.44 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.